Welcome to our dedicated page for FSTX news (Ticker: FSTX), a resource for investors and traders seeking the latest updates and insights on FSTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSTX's position in the market.
F-star Therapeutics, a biopharmaceutical company, announced a presentation on FS222, a CD137/PD-L1 tetravalent bispecific antibody, at the ESMO-IO Congress 2021. The Phase 1 study aims to evaluate the safety and efficacy of FS222 in patients with advanced malignancies. The study includes an Accelerated Dose Titration component and tumor-specific efficacy cohorts, with ongoing enrollment at key sites in Spain. Chief Medical Officer Louis Kayitalire expressed optimism about the potential of FS222 to address unmet medical needs in cancer treatment.
F-star Therapeutics (NASDAQ: FSTX) will host an R&D Day webinar on December 6, 2021, from 8:00 a.m. to 10:00 a.m. ET. The company will showcase its bispecific antibody discovery platform and discuss its four proprietary clinical programs, with potential milestone payments exceeding $2.2 billion from licensing partnerships. Key speakers include CEO Eliot Forster, CSO Neil Brewis, and CMO Louis Kayitalire. The event will feature a Q&A session, and registration is available online.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced its participation in the 36th annual Society for Immunotherapy of Cancer (SITC) Conference from November 12-14, 2021. Michelle Morrow, Ph.D., will present on the company's bispecific platform, particularly FS118, a LAG-3/PD-L1 bispecific. Additionally, a poster on FS120, an OX40/CD137 dual T cell agonist, demonstrated enhanced antitumor activity in combination with PD-1. Ongoing trials for FS118 show promising safety and tolerability, while FS120's Phase 1 study aims to optimize dosing for further clinical applications.
F-star Therapeutics (NASDAQ: FSTX) reported its third quarter 2021 results, highlighting significant advancements in its bispecific antibody programs. As of September 30, 2021, cash stood at $71.1 million, bolstered by a $17.5 million collaboration agreement with Janssen Biotech expected in Q4 2021. The net loss for the quarter was $10.8 million, or $0.52 per share, compared to a loss of $3.5 million in Q3 2020. Notable partnerships with AstraZeneca and Janssen are set to enhance the company's clinical trials and therapeutic reach, particularly in cancer treatments.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced a conference call and webcast scheduled for November 10, 2021, at 9:00 a.m. EST to discuss its third-quarter 2021 financial results and provide a corporate update.
F-star is focused on developing next-generation immunotherapies for cancer treatment and has four second-generation immuno-oncology therapeutics in clinical trials. The company has a strong intellectual property position with over 500 patents and has secured multiple partnerships addressing significant unmet needs in oncology and other areas.
F-star Therapeutics, Ltd. (NASDAQ: FSTX) has announced a collaboration with Janssen Biotech, Inc., enabling Janssen to develop up to five bispecific antibodies using F-star’s proprietary platforms. This agreement grants Janssen a worldwide, exclusive license for research and commercialization. F-star will receive $17.5 million upfront and could earn up to $1.35 billion in milestones, along with tiered royalties on net sales. The collaboration aims to leverage F-star's innovative technology, which could significantly impact cancer treatment.
Abcuro, Inc., a clinical-stage biotechnology company focused on therapies for autoimmune diseases and cancer, has appointed Darlene Deptula-Hicks to its Board of Directors. With over 30 years of experience in the life sciences sector, she previously served as CFO for several companies, including F-star Therapeutics (NASDAQ:FSTX) and T2 Biosystems (NASDAQ:TTOO). Her expertise in growth strategies and capital raising is expected to boost Abcuro's clinical development initiatives, particularly for its lead program, ABC008, which has received Orphan Drug Designation from the FDA.
F-star Therapeutics (NASDAQ: FSTX) reported promising preclinical data on FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist. The data from a pivotal GLP Non-Human primate study indicated a wide therapeutic window, with a highest non-severely toxic dose of 30mg/kg. Key pharmacodynamic biomarkers showed significant increases in CD4+ and CD8+ T cell proliferation. The study's Accelerated Dose Titration component is complete, with plans for a combination study with KEYTRUDA expected to start in Q3 2022. Updates on study progress will be shared later this year.
F-star Therapeutics (NASDAQ: FSTX), a biopharmaceutical firm, is set to participate in the H. C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Eliot Forster will present and conduct one-on-one meetings during the event. Attendees can access the video webcast of the presentation starting at 7 a.m. on September 13 through a provided link. A replay will be available for 90 days. F-star focuses on developing bispecific immunotherapies aimed at enhancing cancer treatment efficacy.
F-star Therapeutics (NASDAQ: FSTX) announced its second quarter 2021 financial results and a corporate update on August 12, 2021. The company is advancing its clinical development strategy for FS118, a bispecific antibody targeting LAG-3 and PD-L1, to include checkpoint inhibitor naïve patients, particularly those with non-small cell lung cancer and diffuse large B-cell lymphoma. The firm reported cash reserves of over $80 million after a successful public offering, despite a net loss of $15.6 million for the quarter. Collaborations with AstraZeneca and MSD aim to enhance therapeutic combinations.
